Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

nizatidine

nizatidine
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Axid AR CAPSULE, ORAL 150 mg, 300 mg    
Axid SOLUTION, ORAL 15 mg/mL    
Axid TABLET, ORAL 75 mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

NOTES

nizatidine (Axid)

  • 150 mg capsule PO Daily
  • 150 mg capsule PO BID
  • 300 mg capsule PO qhs

famotidine (Pepcid)

  • 20 mg tablet PO Daily
  • 20 mg tablet PO BID
  • 40 mg tablet PO qhs
  

nizatidine (Axid)

  • 75 mg tablet PO BID

cimetidine (Tagamet)

  • 200 mg tablet PO BID
  

nizatidine (Axid)

  • 15 mg/mL solution oral (PEDS)

famotidine (Pepcid)

  • Contact Prescriber (PEDS)

 

 

If H2 blocker prescribed with PPO, discontinue H2 blocker after 48 hours. Exception if GI physician -- check with physician that H2 blocker is not being used for a non-GI use prior to discontinuing.

 

Updated: April 2020 (Zantac liquid removed from market)

Last updated: Apr. 22, 2020






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved